1 |
Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6.
DOI
ScienceOn
|
2 |
Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32.
DOI
ScienceOn
|
3 |
National Health Insurance Corporation. The Criterias for the Medical Care Benefits. 2010. Available from: http://www.nhic.or.kr.
|
4 |
Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-7.
DOI
ScienceOn
|
5 |
Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
DOI
ScienceOn
|
6 |
Choe BH, Lee JH, Jang YC, Jang CH, Oh KW, Kwon S, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-8.
DOI
ScienceOn
|
7 |
Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78.
DOI
ScienceOn
|
8 |
Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology 2007;132:1586-94.
DOI
ScienceOn
|
9 |
Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
DOI
ScienceOn
|
10 |
Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009;43:1008-10.
DOI
ScienceOn
|
11 |
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudinerefractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108.
DOI
ScienceOn
|
12 |
Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009;14:985-93.
DOI
ScienceOn
|
13 |
Chang TT, Gish RG, de Man RA, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
DOI
ScienceOn
|
14 |
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44.
DOI
ScienceOn
|
15 |
Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-90.
|
16 |
Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 2005;43:920-3.
DOI
ScienceOn
|
17 |
Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-91.
DOI
ScienceOn
|
18 |
Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
DOI
ScienceOn
|
19 |
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
DOI
ScienceOn
|
20 |
Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
DOI
ScienceOn
|
21 |
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR. Predictive Factors and Efficacy of Lamivudine Treatment in Chronic Hepatitis B Infection. Korean J Gastroenterol 2003;42:303-12.
|
22 |
Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
DOI
ScienceOn
|
23 |
Lee KS, Kim DJ, Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007;13:447-88.
DOI
ScienceOn
|
24 |
Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudineresistant HBV. Antivir Ther 2005;10:625-33.
|
25 |
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
DOI
ScienceOn
|
26 |
Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, Frederick D, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008;47:1863-71.
DOI
ScienceOn
|
27 |
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudinerefractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49.
DOI
ScienceOn
|
28 |
Hwang SK, Park SM, Choe BH, Kim JM, Kim JO, Kim YM, et al. Therapeutic efficacy of adefovir dipivoxil in korean children and adolescents with chronic hepatitis b who have developed lamivudine resistance. Korean J Pediatr Gastroenterol Nutr 2008;11:143-9.
|
29 |
Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27.
|
30 |
Lee JM, Kim HJ, Park JY, Lee CK, Kim do Y, Kim JK, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther 2009;14:705-12.
|
31 |
Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-93.
|
32 |
Kurbegov AC, Sokol RJ. Hepatitis B therapy in children. Expert Rev Gastroenterol Hepatol 2009;3:39-49.
DOI
ScienceOn
|
33 |
Sokal EM, Kelly D, Wirth S, Mizerski J, Dhawan A, Frederick D. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008;48:512-7.
DOI
ScienceOn
|